Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nanovesicles for Targeted Drug Delivery
share announcement

Nanovesicles for Targeted Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 15250

Special Issue Editor

Prof. Dr. Sung Tae Kim

E-Mail Website
Guest Editor
Department of Pharmaceutical Engineering, Inje University, Gimhae 50834, Republic of Korea
Interests: biodegradable polymers; nanostructured drug and gene delivery system; interdisciplinary research of nano/bio; bioactive agents; therapeutics; active targeting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Targeted drug delivery systems are advanced vesatile platforms for improving therapeutic efficacy while reducing side effects. Nanovesicles are promising carriers of therapeutic, bioactive, and theranostic agents for targeted drug delivery systems, such as passive or active targeting systems, since they deliver these agents to the target site effectively. Such nanovesicles, which are composed of natural and/or synthetic materials, are designed to couple with specific ligands depending on the target’s specific cells and tissues. In recent years, the use of bio-inspired nanovesicles has been attempted in targeted drug delivery systems. As such, various nanovesicles have been studied in order to provide many attributes of the “magic bullet”. However, the use of nanovesicles remains a topic of long-standing interest and represents a challenge to researchers and clinicians.

This Special Issue of Pharmaceutics will focus on new approaches to nanovesicles for targeted drug delivery. Potential topics include, but are not limited to, the design, fabrication, and application of nanovesicles for targeted drug delivery. Full-length original research papers, short communications, and reviews are all welcome.

Prof. Dr. Sung Tae Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanovesicles
  • nanocarriers
  • lipid-based carriers
  • polymer-based carriers
  • theranostics
  • smart drug delivery
  • targeted drug delivery

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1503 KiB  
Article
Repurposing of Fluvastatin as an Anticancer Agent against Breast Cancer Stem Cells via Encapsulation in a Hyaluronan-Conjugated Liposome
by Ji Su Yu, Dae Hwan Shin and Jin-Seok Kim
Pharmaceutics 2020, 12(12), 1133; https://doi.org/10.3390/pharmaceutics12121133 - 24 Nov 2020
Cited by 7 | Viewed by 2046
Abstract
Fluvastatin (FLUVA), which is a common anti-hypercholesterolemia drug, exhibits potential anticancer activity as it suppresses the proliferation, angiogenesis, and metastasis of breast cancer cells via inhibiting 3-hydroxy-methyl glutaryl-coenzyme A (HMG-CoA) reductase. In this study, hyaluronan-conjugated FLUVA-encapsulating liposomes (HA-L-FLUVA) were evaluated for their anticancer [...] Read more.
Fluvastatin (FLUVA), which is a common anti-hypercholesterolemia drug, exhibits potential anticancer activity as it suppresses the proliferation, angiogenesis, and metastasis of breast cancer cells via inhibiting 3-hydroxy-methyl glutaryl-coenzyme A (HMG-CoA) reductase. In this study, hyaluronan-conjugated FLUVA-encapsulating liposomes (HA-L-FLUVA) were evaluated for their anticancer efficacy in vitro and in vivo. The particle size, zeta potential, and encapsulation efficiency of HA-L-FLUVA were 158.36 ± 1.78 nm, −24.85 ± 6.26 mV, and 35%, respectively. Growth inhibition of breast cancer stem cells (BCSCs) by HA-L-FLUVA was more effective than that by free FLUVA. The half maximal inhibitory concentration (IC50) values of FLUVA, L-FLVUA, and HA-L-FLUVA were 0.16, 0.17, and 0.09 μM, respectively. The in vivo anticancer effect of HA-L-FLUVA in combination with doxorubicin (DOX) was more effective than that of free FLUVA, free DOX, and HA-L-FLUVA. The longest survival of mice was achieved by treatment with FLUVA (15 mg/kg) and HA-L-FLUVA (15 mg/kg) + DOX (3 mg/kg), followed by HA-L-FLUVA (15 mg/kg), Dulbecco’s phosphate buffered saline, and DOX (3 mg/kg). No more than 10% body weight loss was observed in the mice injected with FLUVA, indicating that the drug was not toxic. Taken together, these results indicate that HA-L-FLUVA could serve as an effective anticancer drug by inhibiting the growth of both breast cancer cells and cancer stem cells. Full article
(This article belongs to the Special Issue Nanovesicles for Targeted Drug Delivery)
►▼ Show Figures

Figure 1

18 pages, 2924 KiB  
Article
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
by Walid Kamoun, Elden Swindell, Christine Pien, Lia Luus, Jason Cain, Minh Pham, Irawati Kandela, Zhaohua Richard Huang, Suresh K. Tipparaju, Alexander Koshkaryev, Vasileios Askoxylakis, Dmitri B. Kirpotin, Troy Bloom, Mari Mino-Kenudson, James D. Marks, Alena Zalutskaya, Wiam Bshara, Carl Morrison and Daryl C. Drummond
Pharmaceutics 2020, 12(10), 996; https://doi.org/10.3390/pharmaceutics12100996 - 20 Oct 2020
Cited by 5 | Viewed by 2559
Abstract
Ephrin receptor A2 (EphA2) is a member of the Ephrin/Eph receptor cell-to-cell signaling family of molecules, and it plays a key role in cell proliferation, differentiation, and migration. EphA2 is overexpressed in a broad range of cancers, and its expression is in many [...] Read more.
Ephrin receptor A2 (EphA2) is a member of the Ephrin/Eph receptor cell-to-cell signaling family of molecules, and it plays a key role in cell proliferation, differentiation, and migration. EphA2 is overexpressed in a broad range of cancers, and its expression is in many cases associated with poor prognosis. We recently developed a novel EphA2-targeting antibody-directed nanotherapeutic encapsulating a labile prodrug of docetaxel (EphA2-ILs-DTXp) for the treatment of EphA2-expressing malignancies. Here, we characterized the expression of EphA2 in bladder cancer using immunohistochemistry in 177 human bladder cancer samples and determined the preclinical efficacy of EphA2-ILs-DTXp in four EphA2-positive patient-derived xenograft (PDX) models of the disease, either as a monotherapy, or in combination with gemcitabine. EphA2 expression was detected in 80–100% of bladder cancer samples and correlated with shorter patient survival. EphA2 was found to be expressed in tumor cells and/or tumor-associated blood vessels in both primary and metastatic lesions with a concordance rate of approximately 90%. The EphA2-targeted antibody-directed nanotherapeutic EphA2-ILs-DTXp controlled tumor growth, mediated greater regression, and was more active than free docetaxel at equitoxic dosing in all four EphA2-positive bladder cancer PDX models. Combination of EphA2-ILs-DTXp and gemcitabine in one PDX model led to improved tumor growth control compared to monotherapies or the combination of free docetaxel and gemcitabine. These data demonstrating the prevalence of EphA2 in bladder cancers and efficacy of EphA2-ILs-DTXp in PDX models support the clinical exploration of EphA2 targeting in bladder cancer. Full article
(This article belongs to the Special Issue Nanovesicles for Targeted Drug Delivery)
►▼ Show Figures

Figure 1

12 pages, 2259 KiB  
Article
Docetaxel-Loaded Chitosan-Cholesterol Conjugate-Based Self-Assembled Nanoparticles for Overcoming Multidrug Resistance in Cancer Cells
by Chao-Feng Mu, Fude Cui, Yong-Mei Yin, Hyun-Jong Cho and Dae-Duk Kim
Pharmaceutics 2020, 12(9), 783; https://doi.org/10.3390/pharmaceutics12090783 - 19 Aug 2020
Cited by 7 | Viewed by 2662
Abstract
Cholesteryl hemisuccinate (CHS)-conjugated chitosan (CS)-based self-assembled nanoparticles (NPs) were developed for enhancing the intracellular uptake of docetaxel in multidrug resistance (MDR)-acquired cancer cells. CHS-CS was successfully synthesized and self-aggregation, particle size, zeta potential, drug entrapment efficiency, and in vitro drug release of docetaxel-loaded [...] Read more.
Cholesteryl hemisuccinate (CHS)-conjugated chitosan (CS)-based self-assembled nanoparticles (NPs) were developed for enhancing the intracellular uptake of docetaxel in multidrug resistance (MDR)-acquired cancer cells. CHS-CS was successfully synthesized and self-aggregation, particle size, zeta potential, drug entrapment efficiency, and in vitro drug release of docetaxel-loaded CHS-CS NPs were tested. The optimized NPs had a mean hydrodynamic diameter of 303 nm, positive zeta potential of 21.3 mV, and spherical shape. The in vitro release of docetaxel from the optimized CHS-CS NPs in different pH medium (pH 6.0 and 7.4) revealed that the release was improved in a more acidic condition (pH 6.0), representing a tumor cell’s environment. The superior MDR-overcoming effect of docetaxel-loaded CHS-CS NPs, compared with docetaxel solution, was verified in anti-proliferation and cellular accumulation studies in MDR-acquired KBV20C cells. Thus, CHS-CS NPs could be potentially used for overcoming the MDR effect in anticancer drug delivery. Full article
(This article belongs to the Special Issue Nanovesicles for Targeted Drug Delivery)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

42 pages, 4013 KiB  
Review
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
by Dongyoon Kim, Quoc-Viet Le, Yina Wu, Jinwon Park and Yu-Kyoung Oh
Pharmaceutics 2020, 12(12), 1233; https://doi.org/10.3390/pharmaceutics12121233 - 18 Dec 2020
Cited by 22 | Viewed by 7383
Abstract
Genome-editing technology has emerged as a potential tool for treating incurable diseases for which few therapeutic modalities are available. In particular, discovery of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system together with the design of single-guide RNAs (sgRNAs) has sparked medical [...] Read more.
Genome-editing technology has emerged as a potential tool for treating incurable diseases for which few therapeutic modalities are available. In particular, discovery of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system together with the design of single-guide RNAs (sgRNAs) has sparked medical applications of genome editing. Despite the great promise of the CRISPR/Cas system, its clinical application is limited, in large part, by the lack of adequate delivery technology. To overcome this limitation, researchers have investigated various systems, including viral and nonviral vectors, for delivery of CRISPR/Cas and sgRNA into cells. Among nonviral delivery systems that have been studied are nanovesicles based on lipids, polymers, peptides, and extracellular vesicles. These nanovesicles have been designed to increase the delivery of CRISPR/Cas and sgRNA through endosome escape or using various stimuli such as light, pH, and environmental features. This review covers the latest research trends in nonviral, nanovesicle-based delivery systems that are being applied to genome-editing technology and suggests directions for future progress. Full article
(This article belongs to the Special Issue Nanovesicles for Targeted Drug Delivery)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop